Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Troy Cox, Dan Handley, Ed Simcox, More

Sophia Genetics: Troy Cox
Sophia Genetics has named former Foundation Medicine CEO Troy Cox chairman of its board of directors, effective March 1. Cox will replace Antoine Duchateau, whom the company said will remain on the board. Cox, who also has held executive positions at US BioOncology and Genentech, joined the Sophia Genetics board in July 2019.
Predictive Oncology: Dan Handley
Predictive Oncology has appointed Dan Handley to its board of directors. Handley is a professor and director of the Clinical and Translational Genome Research Institute of Southern California University. Previously, he was chief scientific officer of the Clinical and Translational Genome Research Institute, a Florida-based non-profit. He also previously served as chief scientific officer for Advanced Healthcare Technology Solutions; as a senior researcher at Procter & Gamble; a senior administrator, researcher, and laboratory manager at the David Geffen UCLA School of Medicine; and as a founding biotechnology inventor for the National Genetics Institute.
LifeOmic: Ed Simcox
Precision medicine software firm LifeOmic has named Ed Simcox as its new chief strategy officer. Simcox joins LifeOmic from the US Department of Health and Human Services, where he served as chief technology officer and acting chief information officer. Prior to this, Simcox was director of US health care strategy, partnerships, and product development for AT&T. He also served as healthcare practice leader at Logicalis US, a global IT firm.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.